Pfizer Inc (PFE)

He owned it but sold. Free cash flow is not abundant and it has a lot of debt. It will take time to turn around but pays a good dividend.

Pays a 7% dividend. Something good must be coming out of their Seagen acquisition. The pipeline looks promising.

Once upon a time, he really liked it. Beaten up for inability to bring forward a weight-loss drug; that may or may not be a realistic critique of this stock long term. Analyst community is really...just...waiting. He sold last year, not ready to come back in. Solid company, an improved oncology pipeline might be a reason to get back in.

It can bottom here. He believes in their Seagen acquisition.

Hangover from its Covid highs. Working on an obesity pill, but pulled back on it. Opportunities in the pipeline. Owned in his income growth portfolio for the yield. Despite the chart, likes it here. Fairly cheap, hopefully hitting a bottom (knock wood).

Failure in a couple of drugs. Huge research program; they will find new drugs. Outstanding stock to accumulate because, at some point, they're going to announce a new drug and the stock will pop. Yield is close to 7-8%.

Thinks dividend is safe, but may be challenged. Spent billions on acquisitions, but hasn't gained much. Not growing. Any boost to bottom line comes from cost cuts. Downhill since Covid, pipeline not strong. Better opportunities in the pharma space, such as MRK. 

You'd have thought they'd be hit more by tariffs, as Trump hammers on that many drug components are made overseas. So the market must be thinking tariffs will benefit pharma, to explain why this name is up on such a tremendously down day. Keeping people guessing and on a knife's edge isn't a bug of the current US administration, it's a feature.

His healthcare investments focus on health management like UNH and medical devices.

It's cheap, but for a reason. Sees no growth, despite a big acquisition. Consider Merck or Amgen for perhaps more growth.

It reports Tuesday. Their anti-cancer drugs still haven't broken up to justify the cost of acquiring them. Good news would pop shares up. Little downside now.

It has over paid for some M&A. It is a deep value play but needs a catalyst. It has had some management change but recovery is not part of their investment style. They sold about a year and a half ago.

Market's been tough on it. Investing $2B a year on R&D, made some acquisitions. Lots in the pipeline is up in the air. Stock will pop eventually back to its historical $40-45, and then he'll probably cash in. In his income fund, with the yield at 6%.

It's too low to sell. Collect the dividend and see if we get good news about the Seagen acquisition.

If he's right about a correction in 2025, money managers will rotate into defensive areas like staples, utilities, healthcare and REITs. Their chart was in a big downtrend in recent years. PFE's chart has a double bottom this year. Relative strength is moving up. Also, volumes has popped around $25 (trough). The risk/reward is good. You're paid 6.5% to wait, too. $25 is big technical support.

Acquisitions in oncology weren't enough for the stock. A long-term play. Slightly disappointing on the year, but oncology segment will continue to do well going forward.